Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276524 | 0.99 | CTSB (0.42) | CTSBKDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3283641 | 0.94 | CTSB (0.44) | CTSBKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4615403 | 0.89 | CTSB (0.50) | CTSBKDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3048826 | 0.85 | CTSB (0.41) | CTSBKDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3039920 | 0.79 | CTSB (0.61) | CTSBKDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL1942574 | 0.78 | CTSB (0.39) | CTSBKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3040552 | 0.77 | CTSB (0.43) | CTSBKDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3049466 | 0.77 | CTSB (0.49) | CTSBKDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3314022 | 0.76 | ALDH1A1 (0.32) | CTSBKDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL3050935 | 0.76 | CTSB (0.63) | CTSBKDM4ESMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1910347-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | CTSB 404/4885KDM4E 4409/4885SMN1; SMN2 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.